NYMX - ナイモックス・ファ―マシュ―ティカル (Nymox Pharmaceutical Corporation) ナイモックス・ファ―マシュ―ティカル

 NYMXのチャート


 NYMXの企業情報

symbol NYMx
会社名 Nymox Pharmaceutical Corp. (ナイモックス・ファ―マシュ―ティカル)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ニモックス・ファーマシューティカル(Nymox Pharmaceutical Corp)はカナダのバイオ医薬品会社である。同社は良性前立腺肥大症(BPH)の治療と低悪性度限局性前立腺癌治療薬候補NX-1207の開発を主とする。同社は高齢者向けの製品の研究・開発事業を通じて行う。同社はタバコ製品の使用を検出するために尿または唾液を使用するNicAlertおよびTobacAlert試験を販売している。同社はまた、販売されている製品、治験薬、その他の治療上・診断上の適応症の権利を所有する。また、アルツハイマー病の治療・予防のためのスタチン系薬剤の使用に関する権利を有する。子会社はNymox CorporationとSerex Incを含む。Nymox CorporationはNicAlertおよびTobacAlertの研究・開発を行い、Serex IncはNicAlertおよびTobacAlertの研究・開発・製造を行う。  ナイモックス・ファ―マシュ―ティカルは、カナダのバイオ医薬品会社。肥大前立腺、大腸菌、アルツハイマ―などの治療薬開発のほかに、タバコやアルツハイマ―およびその他障害向け診断薬の開発を手掛ける。主な製品は、尿によるアルツハイマ―病診断薬「AlzheimAlert」や、唾液によるニコチン検査薬「ニコアラ―ト」など。本社はケベック州セントロ―レンス。   Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.
本社所在地 9900 Cavendish Boulevard Suite 306 Saint-Laurent Quebec H4M 2V2 CAN
代表者氏名
代表者役職名
電話番号
設立年月日 34820
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 24人
url www.nymox.com
nasdaq_url https://www.nasdaq.com/symbol/nymx
adr_tso
EBITDA EBITDA(百万ドル) -12.95303
終値(lastsale) 2.375
時価総額(marketcap) 144264625
時価総額 時価総額(百万ドル) 96.42420
売上高 売上高(百万ドル) 0.37618
企業価値(EV) 企業価値(EV)(百万ドル) 91.38420
当期純利益 当期純利益(百万ドル) -12.99294
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Nymox Pharmaceutical Corp revenues increased from $88K to $240K. Net loss decreased 8% to $5.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General_Administrative decrease from $647K (expense) to $455.8M (income) Research and development - Balancing val decrease from $1.8M (expense) to $454M (income).

 NYMXのテクニカル分析


 NYMXのニュース

   The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering  2020/01/07 12:57:46 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 6.) Agile Therapeutics Inc (NASDAQ: AGRX ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Audentes Therapeutics Inc (NASDAQ: BOLD ) BioNTech SE – ADR (NASDAQ: BNTX ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Inspire Medical Systems Inc (NYSE: INSP ) Nevro Corp (NYSE: NVRO ) Nymox Pharmaceutical Corp (NASDAQ: NYMX ) (announced publication of a peer reviewed research report on the experimental studies for its fexapotide triflutate treatment for prostate enlargement and low-grade prostate cancer) Orthopediatrics Corp (NASDAQ: KIDS ) (announced sale of its adult Vilex business in Tennessee to Squadron Capital and used the proceeds for the repayment of term loan due to Squadron) Oyster Point Pharma Inc (NASDAQ: OYST ) Sanofi SA (NASDAQ: SNY ) (JPMorgan upgraded the shares from Neutral to Overweight, citing an attractive valuation) Soligenix, Inc.
   Nymox Pharmaceutical leads healthcare gainers; Ionis Pharmaceuticals and GenMark Diagnostics among losers  2019/04/17 15:01:44 Seeking Alpha
   Nymox up 6% after FDA meeting on lead drug application  2019/04/16 17:11:36 Seeking Alpha
   Helius Medical: A Failed Clinical Trial, Redacted Data, And Questionable Leadership, Points To An Ineffective Device  2019/01/29 10:00:00 Seeking Alpha
   Momentum Strategies That Continue To Dominate Through January  2019/01/17 21:24:11 Seeking Alpha
   The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering  2020/01/07 12:57:46 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 6.) Agile Therapeutics Inc (NASDAQ: AGRX ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Audentes Therapeutics Inc (NASDAQ: BOLD ) BioNTech SE – ADR (NASDAQ: BNTX ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Inspire Medical Systems Inc (NYSE: INSP ) Nevro Corp (NYSE: NVRO ) Nymox Pharmaceutical Corp (NASDAQ: NYMX ) (announced publication of a peer reviewed research report on the experimental studies for its fexapotide triflutate treatment for prostate enlargement and low-grade prostate cancer) Orthopediatrics Corp (NASDAQ: KIDS ) (announced sale of its adult Vilex business in Tennessee to Squadron Capital and used the proceeds for the repayment of term loan due to Squadron) Oyster Point Pharma Inc (NASDAQ: OYST ) Sanofi SA (NASDAQ: SNY ) (JPMorgan upgraded the shares from Neutral to Overweight, citing an attractive valuation) Soligenix, Inc.
   Nymox Pharmaceutical leads healthcare gainers; Ionis Pharmaceuticals and GenMark Diagnostics among losers  2019/04/17 15:01:44 Seeking Alpha
   Nymox up 6% after FDA meeting on lead drug application  2019/04/16 17:11:36 Seeking Alpha
   Helius Medical: A Failed Clinical Trial, Redacted Data, And Questionable Leadership, Points To An Ineffective Device  2019/01/29 10:00:00 Seeking Alpha
   Momentum Strategies That Continue To Dominate Through January  2019/01/17 21:24:11 Seeking Alpha
   The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering  2020/01/07 12:57:46 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 6.) Agile Therapeutics Inc (NASDAQ: AGRX ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Audentes Therapeutics Inc (NASDAQ: BOLD ) BioNTech SE – ADR (NASDAQ: BNTX ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Inspire Medical Systems Inc (NYSE: INSP ) Nevro Corp (NYSE: NVRO ) Nymox Pharmaceutical Corp (NASDAQ: NYMX ) (announced publication of a peer reviewed research report on the experimental studies for its fexapotide triflutate treatment for prostate enlargement and low-grade prostate cancer) Orthopediatrics Corp (NASDAQ: KIDS ) (announced sale of its adult Vilex business in Tennessee to Squadron Capital and used the proceeds for the repayment of term loan due to Squadron) Oyster Point Pharma Inc (NASDAQ: OYST ) Sanofi SA (NASDAQ: SNY ) (JPMorgan upgraded the shares from Neutral to Overweight, citing an attractive valuation) Soligenix, Inc.
   Nymox Pharmaceutical leads healthcare gainers; Ionis Pharmaceuticals and GenMark Diagnostics among losers  2019/04/17 15:01:44 Seeking Alpha
   Nymox up 6% after FDA meeting on lead drug application  2019/04/16 17:11:36 Seeking Alpha
   Helius Medical: A Failed Clinical Trial, Redacted Data, And Questionable Leadership, Points To An Ineffective Device  2019/01/29 10:00:00 Seeking Alpha
   Momentum Strategies That Continue To Dominate Through January  2019/01/17 21:24:11 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ナイモックス・ファ―マシュ―ティカル NYMX Nymox Pharmaceutical Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)